Clinical trials: Castrate-resistant Prostate Cancer
Castrate Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
This is a single-center, open-label, study of Prostate-Specific Membrane Antigen (PSMA)-targeted radionuclide therapy with 177Lu-PSMA-617 in combination with pembrolizumab in participants with metastatic castrate-resistant…
- Conditions
- Castrate Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Carcinoma
- Trial name
- NCT05766371
- Testing
- Pembrolizumab, 177Lu-PSMA-617
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of California, San Francisco
NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer)
A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors
This is a Phase 1b, 2-part, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of [64Cu]Cu-AKY-2519 and/or [225Ac]Ac-AKY-2519, as well as the preliminary anti-tumor activity…
- Conditions
- NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer), ES-SCLC, Small Cell Lung Cancer Extensive Stage
- Trial name
- BActinium-2 (NCT07887971)
- Testing
- [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging)
- Where
- 2 sites in United States
- Volunteers
- 152 people
- Sponsor
- Aktis Oncology, Inc.
Castration-Resistant Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone
Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer
This randomized phase II trial studies how well enzalutamide with or without radium Ra 223 dichloride in treating patients with castration-resistant prostate cancer that has spread to other places in the body.
- Conditions
- Castration-Resistant Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer
- Trial name
- NCT03344211
- Testing
- Enzalutamide, Laboratory Biomarker Analysis, Radium Ra 223 Dichloride
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Southern California
Breast Cancer, Castration-resistant Prostate Cancer
Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer
The investigators propose to perform a pragmatic, multicenter, open-label, randomised clinical trial to demonstrate the efficacy and safety of either continuing or further de-escalating BMA after a minimum of two years of BMA…
- Trial name
- NCT04549207
- Testing
- Bone modifying agent
- Where
- 5 sites in Canada
- Volunteers
- 240 people
- Sponsor
- Ottawa Hospital Research Institute
Metastatic Castration Resistant Prostate Cancer
A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer
The purpose of this study is to assess the safety and tolerability, describe the dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD [in the absence of establishing…
- Trial name
- MEDI3726 (NCT02991911)
- Testing
- MEDI3726 Post-Chemo, MEDI3726 Pre-Chemo, MEDI3726 & Enzalutamide Combo
- Where
- 5 sites in United States, Switzerland and 1 more
- Volunteers
- 33 people
- Sponsor
- MedImmune LLC
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer
This randomized phase II trial is studying ixabepilone to see how well it works compared to mitoxantrone and prednisone in treating patients with metastatic prostate cancer that has not responded to paclitaxel, docetaxel, or…
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT00058084
- Testing
- ixabepilone, mitoxantrone hydrochloride, prednisone
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Carcinoma of the Head and Neck (SCCHN), Metastatic Castration Resistant Prostate Cancer (mCRPC)
Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors
Evaluation of the combination of avelumab + bempegaldesleukin (NKTR-214 ) in locally advanced squamous cell carcinoma of the head and neck ( metastatic SCCHN) and avelumab + bempegaldesleukin (NKTR-214) + talazoparib or…
- Trial name
- NCT04052204
- Testing
- avelumab, Bempegaldesleukin, talazoparib
- Where
- 5 sites in United States, Belgium and 2 more
- Volunteers
- 3 people
- Sponsor
- Pfizer
Metastatic Castration-resistant Prostate Cancer
Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)
The purpose of this pre-approval access is to provide Niraparib plus Abiraterone Acetate (Nira/AA combination) in the treatment of (a) participant(s) with first line metastatic castration-resistant prostate cancer with specific…
- Trial name
- NCT05401214
- Testing
- Niraparib plus Abiraterone Acetate (Nira/AA) combination, Prednisone/Prednisolone
- Sponsor
- Janssen Research & Development, LLC
Anemia, Fatigue
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
RATIONALE: Epoetin alfa may stimulate red blood cell production and may help improve cancer-related anemia and fatigue. Steroid therapy with dexamethasone may increase the effectiveness of epoetin alfa.
- Conditions
- Anemia, Fatigue, Prostate Cancer
- Trial name
- NCT00060398
- Testing
- epoetin alfa, dexamethasone
- Where
- 140 sites in United States
- Volunteers
- 282 people
- Sponsor
- Eastern Cooperative Oncology Group
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer
CD46 is an exciting new therapeutic target in prostate cancer, with the antibody drug conjugate FOR46 under investigation in phase I clinical trials.
- Trial name
- NCT05245006
- Testing
- 89Zr-DFO-YS5, YS5 antibody, Positron Emission Tomography (PET)/Computerized tomography (CT)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Robert Flavell, MD, PhD
Metastatic Castration-resistant Prostate Cancer
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC
The combination treatment of protein kinase B (AKT) inhibitor, afuresertib, with androgen synthesis enzyme inhibitor, LAE001, may provide an effective treatment for metastatic castration resistant prostate cancer (m-CRPC)…
- Trial name
- NCT04060394
- Testing
- Phase I and Phase II: LAE001/prednisone + afuresertib
- Where
- 17 sites in United States, South Korea
- Volunteers
- 49 people
- Sponsor
- Laekna Limited
Prostatic Neoplasms, Castration-Resistant
A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to evaluate if the anti-tumor activity of JNJ-809 combined with apalutamide is improved compared with apalutamide alone for subjects with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT02906605
- Testing
- JNJ-809, Apalutamide
- Where
- United States
- Sponsor
- Janssen Research & Development, LLC
Metastatic Castration-resistant Prostate Cancer
Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)
PROceed is a multisite, prospective, observational study that describes the real-world use and clinical experience of mCRPC patients treated with the combination of olaparib and abiraterone in the mCRPC setting.
- Trial name
- PROceed (NCT06380738)
- Where
- 36 sites in Germany
- Volunteers
- 111 people
- Sponsor
- AstraZeneca
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma
Molecular Characterization of CTCs and ctDNA in Blood and Plasma Samples From Patients With Metastatic and/or Hormone-Resistant Prostate Cancer
This research trial studies molecular characterization of circulating tumor cells (CTCs) and circulating tumor (ct) deoxyribonucleic acid (DNA) in blood and plasma samples from patients with prostate cancer that has spread to…
- Trial name
- NCT02370355
- Testing
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Southern California
Cancer, Prostate Cancer
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Phase 1/2 multicenter, dose determining, open-label study of ADXS31-142 monotherapy and a combination of ADXS31-142 and pembrolizumab (MK-3475) in participants with metastatic castration-resistant prostate cancer.
- Trial name
- NCT02325557
- Testing
- ADXS31-142, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 50 people
- Sponsor
- Advaxis, Inc.
Castration-resistant Prostate Cancer
Metastasis-directed Therapy in Castration-refractory Prostate Cancer
The aim is to define the postponement of next line systemic treatment (NEST), by the use of metastasis-directed therapy in patients with oligoprogressive castration-refractory prostate cancer.
- Trial name
- MEDCARE (NCT04222634)
- Testing
- Radiotherapy (SBRT) and/or surgery (metastasectomy)
- Where
- Belgium
- Volunteers
- 18 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
This phase I/II trial studies the best dose of M3814 when given together with radium-223 dichloride or with radium-223 dichloride and avelumab and to see how well they work in treating patients with castrate-resistant prostate…
- Conditions
- Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT04071236
- Testing
- Avelumab, Biospecimen Collection, Bone Scan
- Where
- 32 sites in United States
- Volunteers
- 90 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Castration-Resistant Prostate Cancer
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
This Phase 2 study will investigate the safety and clinical activity of vudalimab (XmAb20717) alone or in combination with standard of care anticancer therapies in patients with metastatic castration-resistant prostate cancer…
- Trial name
- NCT05005728
- Testing
- vudalimab + carboplatin + cabazitaxel, vudalimab + olaparib, vudalimab monotherapy
- Where
- 26 sites in United States
- Volunteers
- 72 people
- Sponsor
- Xencor, Inc.
Metastatic Castration Resistant Prostate Cancer
Combination Study of AZD5069 and Enzalutamide.
ACE is a multi-centre proof of concept Phase I/II trial of the CXCR2 antagonist AZD5069, administered in combination with enzalutamide, in patients with metastatic castration resistant prostate cancer(mCRPC).
- Trial name
- ACE (NCT03177187)
- Testing
- AZD5069, Enzalutamide 40 MG
- Where
- 4 sites in Switzerland, United Kingdom
- Volunteers
- 30 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Prostatic Neoplasms
Incidence of Second Primary Malignancies in Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the US
This study is conducted to estimate population-based incidence rates of second primary malignancies among patients with CRPC similar to those treated with Xofigo.
- Trial name
- NCT02788409
- Testing
- Not applicable for study
- Where
- United States
- Volunteers
- 2,234 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.